Weight loss medications should be a first step to prevent heart disease, says the Supreme Heart Diseases Group

The country’s heart disease organization said that exercise and clean diet are not always sufficient for heart health. New recommendations It was released on Friday. The group said that early weight loss medications should be used, making it part of the first line of defense for obese patients.

Novo Nordisk A/S.Wegovy and Elie Lily and PartnersZepbound should be considered when choosing primary treatments to avoid heart disease, the main cause of death in the United States, according to the new guidelines. The non -profit medical association said that common drugs are more effective than lifestyle changes and have less dangers than surgery.

“We have heard about countless positive effects of medicines and obtaining this type of supports from the Administrative Coordination Committee is a great victory,” Mizuho Securities wrote in a memorandum of customers.

The shares of Novo, listed in the United States, briefly increased on Friday after the issuance of the new instructions, and then decreased by 1.1 % from 11:22 am in New York. Lily decreased a decrease previously in the decrease by 2.8 %.

The recommendation of the Administrative Coordination Committee is a departure from its previous recommendation, which called for lifestyle adjustments before obesity medications. Patients should not “try and fail” before they can get strong medications that revolutionized weight loss and proved their ability to improve heart health, he said Olivia GilbertCardiologist in Ears health The Wake Forest Medical Center, which led the work on the new guidelines.

It was explicit in saying that the change was aimed at influencing insurance companies and federal programs that decide prescribed medications that must be covered. Support for cardiologists can lead more patients to adopting medicines and broader insurance coverage to indicate drugs from Novo and Leila, the two main companies compete to control the market Morgan Stanley Analysts He says he swings towards 150 billion dollars at the height of sales within a decade.

“This is incredibly exciting.”.

However, people must “never” cancel their gym membership, according to Genebert. She said that medications will help lose weight and “if anything should increase physical activity.” “They are supposed to work side by side.”

More than 40 % of adults in the United States suffer from obesity, according to the centers of control and prevention control. The Administrative Coordination Committee said that the uncertainty about covering insurance is a great obstacle to treatment, noting that there is “a continuous need to improve access to these treatments.”

Doctors can determine who is qualified for treatment to ward off heart complications based on the body mass index, an account that includes weight and height, or other risk factors, according to the new guidelines.

Gilbert said that the relationship between obesity and heart health is not new, but patients need to lose 10 % of the body’s weight to reduce the risk of cardiovascular and 15 % of relevant deaths. She said that drug therapy may be the best accessible way to get there.

Do not cover many insurance companies, which cost about $ 1,000 for one month without insurance, but they are also available at lower prices for consumers who buy them directly with cash. The new ACC instructions can affect negotiations with private insurance companies, medicare, medicaid, and US government insurance programs for the elderly and the poor, according to Gilbert. While most Medicare and Medicaid plans are paid for weight loss medications for diabetics, they are not currently covered with obesity.

In March of last year, the Food and Drug Administration agreed to Wegovy from Novo to reduce the risk of heart death and blood vessels, heart attacks and strokes in patients with weight gain and heart disease, making it the first of drugs that lose the adopted weight to prevent potential heart problems. While the agency has not yet cleared night to treat cardiovascular diseases, it has cut deaths from heart failure in a study in the late stage last year.

Lily welcomed the change, saying that it enhances the importance of treating obesity early and effectively. Novo praised the step of the Administrative Coordination Committee as it reflects the “scene of today’s treatment.”